Edward Hibben - Catabasis Pharmaceuticals Chief Business Officer
Executive
Mr. Edward Hibben is Chief Business Officer of Catabasis Pharmaceuticals, Inc. Previously, he served as our Senior Vice President, Corporationrationrate Development from April 2015 to February 2017. From September, 2010 to April, 2015, he was Senior Vice President, Corporationrationrate Development at Ensemble Therapeutics, a biopharmaceutical company that discovers and develops small molecule therapies for cancer and other serious diseases. Prior to Ensemble, Mr. Hibben was Chief Business Officer at Cequent Pharmaceuticals until its merger with MDRNA, Inc., and was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group, until its sale to Pfizer since 2017.
| Age | 57 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 617 349 1971 |
| Web | http://www.catabasis.com |
Catabasis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (20.32) % which means that it has lost $20.32 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (210.26) %, meaning that it created substantial loss on money invested by shareholders. Catabasis Pharmaceuticals' management efficiency ratios could be used to measure how well Catabasis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 713 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Catabasis Pharmaceuticals has a current ratio of 34.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Catabasis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Catabasis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catabasis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catabasis to invest in growth at high rates of return. When we think about Catabasis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellie Berger | Scholastic | N/A | |
| Kevin Miller | Olympic Steel | N/A | |
| Katy Liu | Visionary Education Technology | 62 | |
| Susan English | Lincoln Educational Services | N/A | |
| Harley dEntremont | Visionary Education Technology | 70 | |
| Richard Nelson | Acco Brands | N/A | |
| Mary Scherer | Cardinal Health | N/A | |
| Stephen Ace | Lincoln Educational Services | 60 | |
| Paul Daniel | Acco Brands | 58 | |
| Pamela Kimmet | Cardinal Health | 60 | |
| Cassandra Powers | Olympic Steel | N/A | |
| Valerian Thomas | Lincoln Educational Services | 61 | |
| Matt Sims | Cardinal Health | N/A | |
| Aaron Alt | Cardinal Health | 51 | |
| Cristina Juvier | Scholastic | N/A | |
| Michelle SPHR | Olympic Steel | N/A | |
| Matthew Dennis | Olympic Steel | N/A | |
| Renata Couto | Afya | N/A | |
| Francis Giglio | Lincoln Educational Services | N/A | |
| Craig Morford | Cardinal Health | 58 | |
| David Stires | Olympic Steel | N/A | |
Management Performance
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 |
Catabasis Pharmaceuticals Leadership Team
Elected by the shareholders, the Catabasis Pharmaceuticals' board of directors comprises two types of representatives: Catabasis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catabasis. The board's role is to monitor Catabasis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catabasis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catabasis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Director | ||
| Angelika Fretzen, Senior Vice President - Product Development | ||
| Gregg Lapointe, Director | ||
| Rick Modi, Chief Business Officer | ||
| Joanne Donovan, Chief Medical Officer | ||
| Deirdre Cunnane, Senior Vice President General Counsel | ||
| Michael Jirousek, Co-Founder and Member of Scientific Advisory Board | ||
| Michael Kishbauch, Director | ||
| Edward Hibben, Chief Business Officer | ||
| Joanne Beck, Director | ||
| Ian Sanderson, CFO, Treasurer | ||
| Burt Adelman, Director | ||
| Deirdre JD, Sr. VP and General Counsel | ||
| Kenneth Bate, Director | ||
| Hugh Cole, Director | ||
| Jill Milne, Co-Founder, CEO and President and Director | ||
| Andrea Matthews, IR Contact Officer | ||
| Nicholas Galakatos, Director | ||
| Ron Laufer, Director | ||
| Michael Ross, Chairman of the Board | ||
| Andrew Nichols, Sr. VP of Research | ||
| Ted Hibben, Sr. VP of Corporate Devel. |
Catabasis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catabasis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 | |||
| Current Valuation | 58.17 M | |||
| Shares Outstanding | 76.95 M | |||
| Shares Owned By Insiders | 0.03 % | |||
| Shares Owned By Institutions | 54.77 % | |||
| Number Of Shares Shorted | 96.27 K | |||
| Price To Earning | (1.24) X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 258.49 X |
Pair Trading with Catabasis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catabasis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catabasis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HP Inc to buy it.
The correlation of HP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HP Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Catabasis Stock
If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |